cyrilzakka/clinical-trials huggingface dataset:
A Cone-beam Computed Tomography Study of Root and Root Canal Morphology of Maxillary Premolars in an Egyptian Subpopulation

to date there is no detailed examination of the root and root canal system of maxillary first and second premolars in an Egyptian subpopulation. in this study the investigators do an Observational analysis of available records of cone-beam computed tomography (CBCT) of root and canal morphology in the permanent maxillary first and second premolars in this population

Failure of endodontic treatment of upper first and second premolar because of presence of missed canals with lack of data of its morphological variations in the Egyptian population.There are different methods to study canal morphology as tooth clearing and root canal staining, conventional and digital radiographs, radiographic assessment enhanced with contrast media. Recently cone-beam computed tomographic (CBCT) images have been found to be useful in providing accurate anatomic details in 3 dimensions for diagnosis and treatment planning before endodontic therapy.

in this study the investigators do an Observational analysis of available records of cone-beam computed tomography (CBCT) of root and canal morphology in the permanent maxillary first and second premolars in this population

Eligibility Criteria:
Inclusion Criteria:

* CBCT scans with minimum of one premolar.
* Maxillary premolars with fully formed apices

Exclusion Criteria:

* CBCT scans with all maxillary premolars missed.
* Maxillary premolars with open apices
* Maxillary premolars with root resorption
* Maxillary premolars with calcifications or extensive coronal restoration.
* Maxillary premolars with root canal fillings, posts, crown restorations.
Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)

To investigate the use of antibiotic prophylaxis in patients undergoing TURP and TURB. The investigators set up a prospective, randomized controlled trial in which (after exclusion of risk factors) patients will be randomized in receiving levofloxacin (Tavanic) orally or no antibiotics. The exclusion criteria for TURP are a pre-operative transurethral catheter or \> 100 urinary white blood cells in the pre-operative urine sample. The exclusion criteria for TURB are a pre-op catheter or clinical signs of infection.

Main objective:

To investigate the safety of omitting antibiotic prophylaxis in TURP (transurethral resection of the prostate) and TURB (transurethral bladder tumour resection) in patients without a pre-operative catheter or \> 100 WBC in the pre-operative urinary sample (TURP) or clinical signs of urinary infection (TURB).

Secondary objective:

To investigate post-operative bacteriuria after TURB and TURP in our population.

Principal inclusion criterium:

Patients undergoing TURP or TURB.

Primary exclusion criterium:

TURP: pre-operative catheter or \> 100 white blood cells in the pre- operative urinary sample.

TURB: pre-operative catheter or clinical signs of infection (fever, nyctalgia).

Primary endpoint:

Post-operative infection.

Secondary endpoint:

Post-operative bacteriuria.

Eligibility Criteria:
Inclusion Criteria:

* TURP or TURB.

Exclusion Criteria:

* TURP: pre-operative catheter/DJ/nephrostomy or \> 100 white blood cells in the pre- operative urinary sample.

TURB: pre-operative catheter/DJ/nephrostomy or clinical signs of infection (fever, myctalgia).
App-technology to Improve Healthy Lifestyle Behaviors Among Working Adults

The aim of this study is to evaluate if modern technology such as smartphone applications can be used to facilitate lifestyle changes and thereby improve health-related quality of life in gainfully employed persons in the general population in Stockholm, Sweden. The hypothesis is that at follow-up, the intervention group that use the new application will have improved health-related quality of life and other lifestyle habits including diet, physical activity and sleep, as well as biomarkers, compared to a control group.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Ability to communicate in Swedish
* Have access to and use a smartphone

Exclusion Criteria:

-
Metvix Daylight PDT in Actinic Keratosis

Prospective non-interventional study conducted in Australia, Brazil, Mexico and Europe to evaluate clinical practice with Metvix Daylight PDT in the treatment of mild to moderate actinic keratosis of the face/scalp and to assess physician and patient satisfaction.


Eligibility Criteria:
Inclusion Criteria:

* Patients to whom Metvix® Daylight-PDT has already been prescribed by their physician, according to the local label;
Study of Dexmedetomidine in Spine Surgery

The investigators will conduct a prospective randomized double blind study comparing methadone plus methadone and intraoperative dexmedetomidine in multi-level spine surgery in two randomized groups. The investigators plan to document the intraoperative opioid requirements, time to first dose of opioids postoperatively and total opioid consumption in the first 24, 48 and 72 hours. The incidence of intra and postoperative complications will be assessed.

Patients presenting for thoracic and/or lumbar spine surgery with neuromonitoring (MEP/SSEP/EMG)will be recruited. Standard anesthesia monitoring will be performed. Randomized to a placebo or dexmedetomidine arm. Both groups will receive methadone 0.2 mg/kg ideal weight after induction of anesthesia.

The placebo/dexmedetomidine will be loaded at 1 mcg/kg over 20 minutes and then a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure.

Intraoperative analgesia will be provided with fentanyl and dilaudid per the anesthesia team.

Upon closure the study drug will be terminated. Patients will be followed up for 72 hours after surgery. Total opiate consumption and visual analogue scale ratings will be documented.

Intra and postoperative inotrope/pressor requirements will be recorded.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-80 years of age
* Elective multi-level thoracic and/or lumbar spine surgery requiring SSEP, EMG or MEP monitoring

Exclusion Criteria:

* Emergency spine surgery
* Age \< 18 years
* Pregnant patients
* Advanced heart block: Mobitz type II block or atrio-ventricular dissociation in a previous EKG.
* Any individual with stage 4 or greater chronic kidney disease (eGFR\< 30 ml/min) and/or requiring dialysis or liver failure defined as a history of cirrhosis or fulminant hepatic failure
* Any individuals on preoperative methadone therapy
* Preoperative dexmedetomidine use
* Preoperative systolic hypertension defined by a systolic blood pressure greater than 150 mmHg in the surgical admission suite
* Enrolled in another study within 30 days
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K

The purpose of this study is to determine the relative bioavailability and pharmacokinetic profiles from three strengths of a new tablet formulation of ASP015K and to evaluate the safety and tolerability after a single dose of three different strengths of a new tablet formulation.

Eligible subjects will be admitted on Day-1 and remain confined on the unit for 16 days. Each subject will receive a single dose of study drug per the defined treatment periods on the mornings of Day 1, Day 6 and Day11. There will be a minimum of 5 days between each consecutive dose group. Any subject discontinuing the study prior to completion should have all end of study evaluations completed.

Eligibility Criteria:
Inclusion Criteria:

* Subject weighs at least 45 kg and has a body mass index (BMI) of 18-32 kg/m2
* Male subject agrees to sexual abstinence, is surgically sterile or is using a medically acceptable method to prevent pregnancy and agrees to continue using this method until 90 days after the last dose of study drug administration
* Male subject agrees to not donate sperm until 90 days after the dose of study drug administration
* Female subject is surgically sterile or is post-menopausal and is not pregnant and is not lactating
* Subject's 12-lead electrocardiogram (ECG) is normal
* Subject must be capable of swallowing multiple tablets

Exclusion Criteria:

* Subject has a previous history of any clinically significant gastro-intestinal, neurological, renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, malignancy excluding non-melanoma skin cancer or any other medical condition
* Subject has had major GI surgery (such as colectomy, cholecystectomy, etc)
* Subject has a history of consuming more than 14 units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/ substance abuse within past 2 years
* Subject has/had a symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week
* Subject has a positive test for hepatitis C antibody, or positive test for hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody
* Subject has a history of the human immunodeficiency virus (HIV) antibody
* Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold test or T-SPOT® test
* Subject received any vaccine within 60 days
* Subject received an experimental agent within 30 days
* Subject has an absolute neutrophil count (ANC) \< 2500 cells/mm3
* Subject has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days
* Subject has a history of smoking or has used tobacco-containing products and nicotine or nicotine-containing products in the past six months
Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy

This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.

In recent years, scientific literature has focused on the search for new non-invasive diagnostic tools that can identify patients with endometriosis early and easily, thereby reducing diagnostic delay and enabling the immediate initiation of appropriate treatment. Among these, microRNA (miRNA) is emerging as a promising option. Despite recent progress in this field, a predictive biomarker of response to medical therapy or vice versa, resistance to progesterone in endometriosis, has not yet been identified, including among miRNAs. This study aims, therefore, to identify salivary miRNA signatures specific to endometriosis and differentially expressed between responder and non-responder patients to 2 mg dienogest medical therapy. 90 patients diagnosed with endometriosis attending the Obstetrics and Gynecology Clinic at the Santa Maria della Misericordia Hospital in Udine will be enrolled. The investigators will ask them for a salivary sample before starting the progestin therapy. After 4 months from the beginning, the response will be evaluated. The researchers will evaluate the differences between salivary miRNA of the responders vs non-responders.

Eligibility Criteria:
INCLUSION CRITERIA

* Age \> 18 years
* Fertile age
* Clinical-ultrasound diagnosis or histological diagnosis of endometriosis
* Informed consent

EXCLUSION CRITERIA

* Pregnancy
* Pre-menarcheal or post-menopausal status
* Chronic pelvic pain syndrome with or without central sensitization assessed with the Central Sensitization Inventory Test (CSI)
* Neoplasia, diabetes, BMI \> 30 kg/m2, coagulopathies, autoimmune diseases, or other conditions that may affect salivary miRNA measurement
* Currently undergoing progestin therapy
Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease


Eligibility Criteria:
Inclusion Criteria:

* Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA
* Underwritten study consent
* No treatment with acetylcholinesterase inhibitors
* Mini-Mental-State Examination: 12-25 points
* Age: 50-80 Years
* Orale contraception for women of child-bearing age

Exclusion Criteria:

* Mental Disorders
* Other Diseases of the CNS
* Severe Illness
* Contraindication for MRI-Scan
* Contraindication for Galantamin (Reminyl retard®)
* Participation at other clinical trials
Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania

The goal of this research is to evaluate the safety as well as effectiveness of Utapine and Seroquel in bipolar I disorder patients.

Utapine and Serquel belong to anti-bipolar medication family, both are approved by DOH (Department of Health, Taiwan), both has same ingredient but different manufacture. From clinical trial reports, both has excellent effectiveness and safety. The goal of this research is to evaluate the safety as well as effectiveness of Utapine and Seroquel in bipolar I disorder patients for different ingredient and different manufacture.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female age 18-65 years with diagnosis of bipolar I disorder who will be included by DSM-IV criteria made at least one manic or mixepisode record before study entry.
2. Having a minimum score of 20 on the Young Mania Rating Scale (YMRS), plus a score of at least 4 on two of the core YMRS items of Irritability,Speech, Content, and Disruptive/Aggressive Behavior.
3. At least 4 will be on the Severity of Illness item of the Clinical Global ImpressionsNBipolar(CGINBP)assessment tool.
4. Patient with good compliance to study medicine and adherence to study protocol.

Exclusion Criteria:

1. Had received treatment with clozapine within 28 days of the start of the trial.
2. Had been hospitalised for 3 weeks or longer for the index manic episode.
3. DSM-IV criteria for rapid cycling or a current mixed episode.
4. Intolerance or lack of response to quetiapine or clozapine before this trial be diagnosed by investigator.
5. Neurodegenerative disease eg:Parkinson desease、Huntington disease、Pick's disease.
6. Medicine or drugs which can change mental condition be judged by investigator.
7. EKG abnormality
8. Drug or alcohol abuser
Individualized Electronic Intervention to Promote Work Engagement

To determine if physicians who complete brief tasks intended to promote meaning in work and job satisfaction, foster teamwork and social support at work, nuture personal relationships and work-life balance, recognize and build on personal strengths, encourage effective problem solving, and promote positive emotions have improved resilience, meaning in work, and engagement at work.


Eligibility Criteria:
All physicians at Mayo Clinic
The Use of Virtual Reality (VR) and the Change in Emotion in Hong Kong Elders

Virtual Reality (VR) is a technology that combines virtual technology and real-world scenario. In recent years, more and more neuroscience and psychology scientists utilised VR technology in their research. In Hong Kong, many of the community-dwelling elders are immobile. Long-term homestay may negatively affect the emotional state. Measuring the emotional change after administration of VR may prove it as an alternative tool for emotion intervention.

The primary objective is to compare the improvement in the emotional changes between intergeneration interaction and the use of VR technology.

The secondary objective is to evaluate the side effect after using VR technology.

This is a randomized, open label-controlled trial with a crossover design. The subject will be randomized in a ratio of 1:1 into two different intervention groups, the VR group and the Intergeneration Interaction group. After 2 weeks of washout period, the VR group will receive Intergeneration Interaction and vice versa. The intervention phases last approximately 2 hours. The change in the emotional state will be assessed using the Positive and Negative Affect Scale. Any adverse event that causes by the VR will be recorded using the Simulator Sickness Questionnaire(SSQ).

This trial is the first study in Hong Kong to investigate the change of emotional state after the administration of VR technology, targeting community-dwelling elders in Hong Kong.


Eligibility Criteria:
Inclusion Criteria:

* Native Cantonese Speaker

Exclusion Criteria:

-
A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.

The purpose of this study is to determine if using Eprex, to maintain hemoglobin within the normal range, will prevent or delay the progression of left ventricular mass growth.

Cardiovascular disease continues to be the major cause of morbidity and mortality in subjects with renal (kidney) disease. Left ventricular hypertrophy (LVH) has been correlated with a high risk of cardiac and all cause mortality. In the renal population , many factors have been shown to be important in the development of LVH, including anemia. This is a multicentre, open, controlled, randomized trial to determine if maintaining hemoglobin within the normal range delays the progress of left ventricular mass growth. Additionally, this study will evaluated the safety of maintaining hemoglobin within the normal range in pre-dialysis subjects. The trial duration is 24 months. Subjects randomized to the treatment arm will receive Eprex therapy to maintain hemoglobin between 120-140 g/L. Subjects randomized to the control arm will not receive any treatment unless their hemoglobin falls to less than or equal to 90 g/L. Those subjects will then be treated to maintain their hemoglobin between 90-105 g/L. The subjects were to receive injections of Eprex once weekly to maintain hemoglobin levels within the target range for the arm to which they were randomized. The subjects were to receive treatment for up to 24 months.

Eligibility Criteria:
Inclusion Criteria:

* Patients have had a decrease in hemoglobin \>= 10 g/L within the past 12 months and a current hemoglobin level between 110-135 g/L (men) and 100-135 g/L (women) OR a hemoglobin level between 115-125 g/L (men) and 110-120 g/L (women)
* Have a calculated creatinine clearance \<80 mL/min and \>15 mL/min

Exclusion Criteria:

* No uncontrolled hypertension (diastolic blood pressure\>= 105 mm Hg on average for the previous month)

No unstable angina or cardiac procedure within the past 12 months or a planned procedure

* No myocardial infarction with the past 12 months
CARDIOLOGIST Trial: Artificial Intelligence Enabled Electrocardiogram for Atrial Fibrillation Detection

This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of Atrial Fibrillation.


Eligibility Criteria:
Inclusion Criteria:

* Patients in emergency department or inpatient department
* Patients had at least 1 ECG
* Patients cared by non-cardiologist

Exclusion Criteria:

* Patients without history of atrial fibrillation diagnosis.
* Patients without history of long-term NOAC or warfarin usage.
* Patients without history of hemorrhagic stoke or ishemic stroke.
* Patients with low eGFR (\<30 ml/min)
Walking Inclined Plane

The adaptations in kinematics and muscle activity, investigated by 3D gait analysis and dynamic electromyography recordings, will be studied in children with bilateral spastic cerebral palsy during level walking, and before and after a training on a treadmill with a sloped surface (7°). Data will be compared with those obtained in a sample of typically developing (TD) children (controls)

15 CP children and 15 TD children aged 6 to 14 years will take part in this study. Dynamic EMG recordings will be performed as well as kinematic data assessments through a gait analysis system. Three different slopes will be assessed, using a treadmill. The primary outcome measure will be the minimal knee extension value in the stance phase. The changes in kinematics will be overall assessed through the Gait Profile Score (Baker et al.). The details in changes will be assessed through statistical parametric mapping (SPM). The changes in muscle activity induced by the slope will be investigated by statistical parametric mapping of the EMG or kinematic data.

Eligibility Criteria:
Inclusion Criteria for children with CP:

* age = 6-14 years old
* children with cerebral palsy: spastic type, bilateral involvement, forefoot initial contact and/or excessive knee flexion at mid-stance and/or decreased hip extension in late stance.
* GMFCS I or II,
* Score on Gillette scale between 8 and 10
* able to walk at least 10 min without help

Inclusion Criteria for TD children:

* age = 6-14 years old

Exclusion Criteria:

* botulinum toxin injection or lower limb surgery within the last year.
* Uncontrolled seizures
Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)

This study will compare the efficacy, safety and tolerability of intravenous ertapenem versus another intravenous antibiotic in the treatment of moderate to severe diabetic foot infections.


Eligibility Criteria:
Inclusion Criteria:

* Type 1 or 2 Diabetes Mellitus treated with diet or medication
* Clinically or microbiologically documented foot infection below the knee
* Osteomyelitic bone must be removed within 48 hours of study entry

Exclusion Criteria:

* Uncomplicated skin infections
* Infected burn wounds
* Necrotizing fascitis
* Wounds with gangrene that cannot be removed with debridement
* Infections of prosthetic materials
* Foreign materials that can not be removed by surgical debridement
* Patients with another antibiotic 3 days prior to enrollment without evidence of treatment failure and presence of a positive culture
* Insufficient blood flow to the limb requiring a revascularization procedure
Ketorolac Effects on Post-operative Pain and Lumbar Fusion

A double blind prospective randomized trial of IV Ketorolac vs. placebo in management of patients undergoing lumbar one or two level spinal fusions.

Primary objective

- To demonstrate Ketorolac results in decreased postoperative opioid use following posterior spinal fusions during the first 48 hours.

Secondary objectives

* To demonstrate that the use of Ketorolac does not decrease spinal fusion in one or two level instrumented spinal fusions.
* To demonstrate the use of Ketorolac decreases the average length of stay following spinal fusions.


Eligibility Criteria:
Inclusion Criteria:

* 18-85 years of age
* Elective posterior lumbar instrumented fusion
* One- or two-level fusion
* Consent to participate in study, and willing to adhere to study follow up

Exclusion Criteria:

* - - Under age of 18 y/o or over age 85.
* History of renal failure, dialysis or creatinine over 1.50mg/dl
* Active smoker or history of within the last 6 months
* Revision surgery
* Auto/worker compensation
* Active cancer or history of chemotherapy in last 6 months
* Active narcotic use within 3 months of surgery date.
* Infection at operative levels
* Any allergies to NSAIDs or Opioids